Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

New research reveals the gut microbiota’s surprising role in aging and highlights promising therapies to counteract its effects on cellular health. Study: Gut microbial-derived ...

The latest findings on the interaction between cell death and cellular senescence in cancer and their pathophysiological significance have been reviewed by a team from Osaka Metropolitan ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Microsoft Word came out during Ronald Reagan's first term in the Oval Office, and in the decades that have passed between then and now, it has become one of Microsoft's most important and ...

Two new “pioneering” open-access scale-up facilities focused on advancing cellular agriculture are at the centre of a €12.5m investment grant from the Dutch National Growth Fund for Cellular ...

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...

Jan 12 (Reuters) - Drug maker Johnson & Johnson (JNJ.N), opens new tab is exploring a bid to acquire Intra-Cellular Therapies (ITCI.O), opens new tab, a biopharmaceutical company, Bloomberg News ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.

J&J has offered to buy each share of Intra-Cellular for $132, representing a 39% premium to the stock's closing price on Friday. Shares of Intra-Cellular rose 34% to $128 in afternoon trading ...